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Experimental allergic encephalomyelitis (EAE)' is an autoimmune disease of the
central nervous system (CNS) that is induced by immunization of susceptible an-
imal strains with myelin basic protein (MBP) . Thedisease is characterized by lym-
phocyte infiltration leading to CNS lesions, demyelination, and chronic relapsing
paralysis, which are symptoms similar to those seen for multiple sclerosis (MS) in
humans (1-6). Prevention ofEAE by treatment with CD4-specific antibodies (7, 8)
and adoptive transfer of disease symptoms with MBP-specific T helper (Th) cells
(9-16) have implicated CD4+ Th cells as the primary disease-inducing component
of EAE.
The dominantT cell response to MPB in mice of particular MHC haplotypes
is directed towards distinct MBP determinants (16-20) . For example, B10.PL and
PL/J mice (H-2°) respond primarily to an acetylated NH2-terminal epitope, while
SJL/J mice (H-2g) respond primarily to a more COOH-terminal epitope . Recent
studies have indicated that in H-2u mice theT cell response to the dominant NH2-
terminal epitope ofMBP is of limited heterogeneity (21-23) . Molecular character-
ization of theTCRs used by B10.PL-derivedTh cells revealed the use of only two
distinct V/3 gene segments, V/38.2 and VS13, and two distinct Va gene segments,
Va2.3 andVa4.3 (21) . The gene products of either V/3 segment can pair with the
gene products ofeither Va segment to yield atotalof four discrete types ofTh cells .
The majority ofTh cells examined expressed the V08.2 gene segment (84%) while
the remainder expressed the V013 gene segment (16%) . Thedistribution ofVa gene
segments was less skewed among these MBP-specific Th cells with 60% expressing
Va2 .3 and 40% expressing Va4.3 .
Thelimited use ofTCRV region genes in theresponse toMBP allows the appli-
cation of unique strategies of specific immune intervention . Since the majority of
MBP NH2-terminal reactive Th cells in H-2u mice use V08.2, mAbs to V08 (F23 .1,
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KJ16) were administered in vivo in attempts to both prevent and cure EAE (21, 22).
Treatment with V08-specific antibodies led to significant reductions of disease inci-
dence when administered before immunization with an MBP NH2-terminal pep-
tide (93-57°Jo in B10.PL mice; 45-5% in (PL/J x SJL)Fl mice), and to a reversal
of disease symptoms in 12 of 19 (PL/J x SJL)Fi mice when these antibodies were
administered after the first signs of MBP-induced paralysis. Mice that developed
EAE despite antiV(38 antibody treatment developed disease symptoms that were
just as severe as those seen in untreated animals.
There remained several possible explanations for the failure to abolish EAE com-
pletely in mice treated with antiV08 antibodies: (a) In addition to the N112-terminal
epitope, there are several other T cell encephalitogenic epitopes present on the MBP
molecule. T cell responses to these alternative epitopes could have been responsible
for the EAE observed in antiV/38-treated animals. (b) mAb treatment may not have
led to the complete elimination of all V08+ T cells. Residual MBP-specific V#8'
T cells may have led to the observed incidents of autoimmunity. (c) EAE may have
resulted from MBP NH2-terminal-specific T cells that express V(3 regions other
than Vf8. For example, in B10.PL mice, V#13 + T cells reactive to the MBP NH2-
terminal would not have been eliminated by antiVO8 treatment, and these T cells
could have been responsible for the failure ofantiVO8 to completely protect against
EAE.
In an attempt to resolve this issue and to improve antiTCR mAb treatment of
EAE, we initiated experiments in which a combination of V08.2- and V013-specific
antibodies were used to block the response to MBP in B10.PL mice. We report here
that treatment with this combination of antibodies led to a significant reduction in
MBP responsiveness, a near-complete protection against EAE induction and a dra-
matic reversal of paralysis in afflicted animals.
Materials and Methods
Mice.
￿
B10.PL mice (6-10 wk old) were purchased from The Jackson Laboratories (Bar
Harbor, ME) or bred at the California Institute of Technology animal facility.
Myelin Basic Protein.
￿
MBP was prepared from frozen rat or mouse brains purchased from
Pel-Freeze Biologicals (Rogers, AR) according to a previously published protocol (24).
Immunization.
￿
MBP was emulsified with an equal volume of CFA supplemented with
4 mg/ml H37Ra (Difco Laboratories, Inc., Detroit, MI). Mice were immunized in the hind
footpads with 150 hg of MBP. For induction of EAE, mice were also given an intravenous
dose of 75 ng of purified pertussis toxin (List Biological Laboratories, Inc., Campbell, CA)
24 and 72 h after MBP immunization.
Proliferation Assays.
￿
Cells were isolated from draining popliteal and inguinal lymph nodes
10 d after MBP immunization (except where noted). Lymph node cells were resuspended
in Ventrex HL-1 medium and plated at 4 x 105 cells per well in 96-well plates. MBP and
protein A-purified antibodies were added to the cultures as indicated in the text. All samples
were run in triplicate. 4 d later, 1 UCi [5H]Thymidine was added to each well and cells were
collected after an additional 16 h of culture using a PHD cell harvester (Cambridge Tech-
nology, Inc., Cambridge, MA). Counts per minute were determined by liquid scintillation
counting.
Flow Cytometry.
￿
AntiV#8.2 (F23.2) was a gift from Michael Bevan. Anti-V#13 (MR12-4)
was provided by Osami Kanagawa. The antibodies were purified by protein A chromatog-
raphy and then biotinylated with NHS-LC-Biotin (Pierce Chemical Co., Rockford, IL) ac-
cording to the manufacturer's recommendations. Biotinylated antibodies were diluted in PBS
containing 5% FCS and 1 mM Hepes. 106 cells were stained with 20 14g/ml of antibody atZALLER ET AL.
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37 °C for 20 min. Cellswere washed with PBS andthen resuspended in 50,1 of a 1:50 dilu-
tion ofFITC-conjugated streptavidin (PierceChemical Co.). After 20 min at 20°C, cells were
washed twicewith PBS andanalyzed usinga 50H Cytofluorograph (Ortho Diagnostic Systems
Inc., Westwood, MA; 535 nm greenband pass filter with an argonlaserexcitation of488mu).
Results
Antibodies Speckfor V,88.2 and V,813InhibitMBP-specific Lymph Node Proliferation Re-
sponses in BIaPL Mice. Our previous analysis of 33 independent MBP-specific
B10.PL-derived T hybridomas had detected the use of only V08.2 and V013 gene
segments (21). To measure the contribution of T cellsexpressing thesetwoVregion
genes in the response to MBP, specific antibodies were used to block in vitroprolifer-
ationresponsesafterMBPimmunization. Themonoclonal antibodies employed were
F23.2 (V#8.2-specific) (25), and MR12-4 (VO13-specific) (Kanagawa, O., manuscript
in preparation). Constant region isotypeanalysis of these mAbs classified them both
as IgG1/x Lymph node cells from B10PL mice were primed in vivo with MBP and
restimulated in vitro with various concentrations of MBP in thepresence of antiVa
antibodies or an IgGI control antibody (MOPC-31C). Proliferative responsesto MBP
were measured by [3H]thymidine-incorporation and the results are shown in Fig.
1. Both antiV,68.2 and antiV/313 partiallyblockedthe response to MBP At the highest
concentration of MBP used for stimulation (3 uM), the percent inhibitions were
59% for antiVO8.2 and 34% for antiV013 . Simultaneous addition of both anti-
bodies resulted in an 85% inhibition of the response. We conclude that the bulk
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Inhibition ofMBP response with antiTCRmAbs. 10 d after the MBP immuniza-
tion ofB10.PL mice (fiveanimals), draining lymphnode cells were removed, pooled, andrestim-
ulated in vitro with various concentrations of MBP in the presence of the indicated antibodies.
After4 dofculture, cellswere pulsed with (3H]thymidine for 16 h. Each pointrepresents mean
cpm from triplicate measurements with background values (no antigen) between1-4 x 103sub-
tracted. The antibodies were purified by protein A affinity chromatography and added to these
cultures at a finalconcentration of 10 Wg/ml. Similar results were obtained with a finalantibody
concentration of 1 p.g/ml. The experiment was repeated once with similar results.1946
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FIGURE 2 .
￿
Down-modulation of V08.2 T cells following in vivo antibody injections . Groups
ofthree B10.PL mice were injected intraperitoneally with the indicated amounts of either F23.2
(V/38.2-specific) or IgG1 control antibody. 3 d later, lymph node cells were collected, pooled,
purified over nylon wool, and subjected to fluorescence flow cytometry . Cells were stained with
biotinylated F23.2 followed by FITC-conjugated streptavidin . 2 x 10 4 cells were counted for each
histogram . Similar results were obtained with nylon wool-purifiedT cells isolated from the spleens
of the antibody-treated mice.
oftheresponse toMBP in B10.PL mice iscomposed ofVf8.2- andV013-expressing
T cells .
In Vivo Injection ofAnti-V,8 Antibodies Leads to a Long-Term Depletion of Corresponding
V,8-expressingTCells . AntiTCRVregion antibodies can be used to deplete specific
Tcells . To optimize the conditions necessary forTcell depletion, variousconcentra-
tions of antiV08.2 and antiVa13 were injected into the peritoneal cavity of B10.PL
mice . Antibody concentrations in unpurified ascites were determined by compar-
ison toa IgG1 standard in an ELISA. The antibodies were then diluted and injected
without further purification in atotalvolume of 0.1 ml permouse. 72 hlater, periph-
eralTcells were purified over nylon wool and analyzed by fluorescence flow cytom-
etry . A representative histogram is shown in Fig. 2 and the data are summarized
in Table I. At all concentrations tested, injection of both antiVO8.2 and antiVO13
resulted in avirtuallycomplete elimination ofcorrespondingTcells expressing high
levels of surface receptors .
A small population ofT cells expressing lower levels of surface TCRs persisted
following in vivo antibody injection. In fact, the percentage ofT cells present in
this dull staining population appeared to increase after antibody treatment . This
increase was especially noticeable when the lowest concentrations ofantibody (0.125
mg) were injected . Ifsome of the injected antiV13 antibodies remained on the T
cell surface, aresidual dull staining population ofT cells could result from subsatu-ZALLER ET AL .
TABLE I
Depletion of V#8.2 and h#13 T cells
Following In Vitro Antibody Treatment
Various concentrations of either F23 .2 (VO8.2-specific) orMR12-4 (Vol3-specific)
antibody were injected into groups ofthree BIO.PL mice . 3 d later, lymph node
cells were purified over nylon wool and analyzed by quantitative fluorescence
flow cytometry . Cells were stained with either biotinylated F23 .2 or biotinylated
MR12-4 followed by FITC-conjugated streptavidin .
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rated binding of the biotinylated anti-V region antibodies used in the fluorescence
analysis due to competitive binding of the remaininginjected antibodies . However,
no increase over background was seen after cell surface staining with a fluorescein-
conjugated anti-mouse Ig reagent (data not shown) . This indicates that after 72 h,
all of the injected antibodies were cleared from theT cell surface . The observed ele-
vation in the percentage of dull stainingT cells following antibody treatment could
be dueto either the expansion ofpre-existing dull staining populationsor theantibody-
induced down-modulation ofTCR levels on formerly bright-staining T cells .
Mice examined at 4 and 8wk after antibody injections showed identical staining
patterns to the mice examined after 72 h (datanot shown) . 12-16 wk after antibody
injection the depleted T cells began to reemerge. Thus, the elimination of specific
Tcells following a single anti-V region antibody treatmentappears to be a relatively
long-term effect .
Responsiveness toMBP Is Diminished Following In Vivo Administration ofAnti-V,# Anti-
bodies. Since in vivo depletion ofV08.2 and Vf13 T cells was possible, we evalu-
ated the effect of this depletion on the response toMBR B10YL mice were treated
with antiV(38.2 and antiVf13, alone and in combination, or with an IgG1 control
antibody, and then primed in vivo with MBR Draining lymph node cells were iso-
lated 10 dlater and restimulated in vitrowithMBPin thepresence ofvariousblocking
antibodies (Fig. 3) .
Injection of the control antibody had no effect on reactivity toMBR There was
avigorous proliferationresponse that was inhibitable by the in vitroaddition of both
antiV08.2 and antiVO13 . AntiVO8.2 injection reduced, but did not eliminate, re-
activity toMBRTheremainingresponse was inhibited by anti-V#13 butnot signifi-
cantly inhibited by addition of antiV)38.2 . AntiVf13 injection, by itself, did not
lead to asignificant reduction inMBPreactivity . However, the responsewas no longer
significantly inhibited by antiV#13, while it remained susceptible to inhibition by
antiV08.2 . Simultaneous injection of both antiV(38.2 andantiVO13 resulted in the
most extreme reduction inMBP reactivity. However, aminor proliferative response
Antibody Amount
mg
Percent
V/38.21°`"
Percent
V08 .2h'gh
Percent
V013 1°"'
Percent
V013h'gh
IgG1 control 0.500 1 .6 8.5 0 .1 2 .0
Anti-VO8 .2 0.500 2 .1 0.2 ND ND
Anti-V08 .2 0.250 2 .1 0 .1 0.3 1 .9
Anti-V08.2 0.125 2.7 0.0 ND ND
Anti-V013 0.250 1 .5 8 .3 0.5 0 .0
Anti-VO13 0.125 ND ND 0 .9 0 .11948
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FIGURE 3 .
￿
Effect of in vivo mAb treatment on the response to MBP . Groups of three B10.PL
mice were treated in vivo with 250Wg ofthe indicated antibodies and then restimulated in vitro
with a final concentration of 31AM MBP . Various blocking antibodies were added to the in vitro
cultures at a final concentration of 10 ttg/ml . Cells were cultured for 4 d and then pulsed with
[3H]thymidine . Each data point represents the mean cpm from triplicate cultures minus back-
ground . The experiment was repeated once with similar results .
toMBP remained, thatwas not significantly inhibited by either antiVa8.2 or anti-
V013 . This residual response could be theconsequence of subdominantMBP-specific
T cells that might expand after the in vivo elimination of the dominant V08.2 and
V013 MBP-specific T cells. The reactivity of this T cell population is directed to-
wards the MBP NH2-terminal epitope (data not shown) .
Anti-V,(3 Antibody Treatment Is an Effective Therapyfor the Prevention ofEAE in B10.PL
Mice. The considerable reduction in responsiveness toMBP brought on by injec-
tion ofantiV/3antibodies suggestedthat this treatment mightbe effectivein preventing
the induction of EAE . To assess the efficacy of this treatment, B10YL mice were
either left untreated or injected with various mAbs, and thenimmunizedwithMBP
in attempts to induceEAR. Resultsfrom these experiments are summarized in Table
II . 14 of 17 mice (82.4%) that were either untreated or had been injected with an
IgG1 control antibody developed EAR. The average disease severity index of the
animals in this group was 2.2 (see legend to Table II for a description of the severity
index scale) .
9 of 10 mice (90%)pretreated with antiVO13 developedEAR. Disease symptoms
in the afflicted mice were just as severe as those seen in the control mice . Therefore,
antiVO13 pretreatment, by itself, is not an effective therapy forEAR, nor did it even
have anoticeable effect . This is consistent with thein vitro proliferationdata presented
in Fig . 3 which demonstrated that antiVO13 when injected by itself did not reduce
the overall responsiveness to MBP 5 of 20 mice treated with antiVO8.2 developed
EAR. The average severity index of the animals in this group was 0.7 . Therefore,
antiVO8.2 treatment alone can lead to a very significant protection against EAR
(p < 0.005) . This is consistent with previous results that demonstrated a reduction
in EAR incidence in H-2u mice pretreated with mAbs that recognize members ofZALLER ET AL .
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TABLE II
Anti-TCR mAb Treatment Protects Against EAE
S
Groups of B10.PL mice were treated with the indicated antibodies and then immediately
immunized in the hind footpads with 150 Ag ofMBP. 75 ng of purified pertussis toxin was
injected imtravenously at 24 and 48 h after immunization . Mice were then observed daily
for signs ofEAE . Disease severity was graded on a 5-point scale : 0, normal ; 1, loss of tail
tone ; 2, hind limb weakness, difficulty walking ; 3, hind limb paralysis, difficulty turning over ;
4, severe whole body paralysis ; 5, death . The average severity for each group was calculated
in two different ways : (a) by averaging the maximum severity of all of the animals in the
group, and (b) by averaging the maximum severity ofonly the diseased animals in the group .
The arithmetic means and standard deviations are indicated in the table . p values were cal-
culated using the Student's t-test .
p < 0.005 when compared with the control group .
p < 0.001 when compared with the control group and p < 0 .025 when compared with the
anti-VO8.2 treated group .
the Vf38 family (22, 26). The symptoms in the five diseased animals in this group
were just as severe as those seen in the control animals but were slightly delayed
in onset . Pretreatment with a combination of antiV08.2 and V013 proved to be
extremely effective in protecting B10TL mice from EAE . Only 1 of 20 mice (5%)
that hadbeen injected with this combination of antibodies developed signs ofparal-
ysis. The average severity index of the animals in this group was 0.1 . This is a very
significant protection against EAE when compared with control mice (ib < 0.001)
and asignificant protectionwhen compared with anti-V08.2-treated mice (p< 0.025) .
The paralysis in the one mouse that exhibited disease symptoms despite double
antibody treatment wasmild (a loss oftail tone) and extremelydelayed in onsetcom-
pared with control mice (19 d vs . an average of 9.4 d after MBP immunization).
TheT cells responsible for the development of EAE in this single exception could
be either Va8.2 or V013 T cells that were not eliminated by antibody treatment
or subdominant T cells that express as yet uncharacterized V/3 genes . To address
this issue, MBP-induced proliferative responses oflymph node cells isolated from
this animal werecompared with those ofcontrol animals withEAE and double anti-
body-treated mice withoutEAE. Draininglymphnode cells used in this experiment
were isolated 21 d afterMBPimmunization .A proliferative response was measured
in the control animals with EAE that was inhibitable by both antiV08.2 and anti-
V/313 (Fig . 4) . No response toMBP was detected in mice that had received double
antibody treatment and weresymptomfree . This is in contrast to the slight prolifer-
ative response that was detected in lymph node cells removed from double anti-
body-treated animals 10 d afterMBP immunization (Fig . 3) . This difference in re-
Treatment
EAE
incidence
Percent
incidence
Avg .
All
animals
severity
Diseased
animals
Avg . day
of onset
None 11/13 82.4 2 .2 t 1 .4 2 .7 t 1 .1 9.4 t 0.6
IgGl control 3/4
Anti-V#8 .2 5/20 25.0 0.7 t 1 .2' 2.6 t 0.5 11 .4 t 0 .5
Anti-V#13 9/10 90.0 2.7 t 1 .4 3.0 t 1 .2 9.3 t 0 .7
Anti-V08 .2 +
anti-VO13 1/20 5.0 0 .1 t 0.21 1 191950
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FIGURE 4.
￿
Comparisons of the response toMBPin mAb-treated mice with and without EAE.
B10.PL mice were either untreated or treated with injections ofboth antiVS8.2 and antiVO13 .
Mice were then immunizedwithMBPand followed for signs ofEAE. 3wk after immunization,
animals with andwithoutEAEwerekilled. Draining lymphnode cells were collected and assayed
for MBP reactivity as described in the legend to Fig . 3 .
sponsiveness might be due to the delay in removing lymph node cells for analysis .
Indeed, proliferative responses were lower in cells from control animals isolated at
day 21 compared with those of cells isolated at day 10 . A response toMBP was seen
in lymph node cells isolated from theone double antibody-treated mouse that showed
signs ofEAE. This response was not inhibitable by either antiV08.2 or antiV013 .
This implies that EAE in this mouse mayhave been caused by MBP-specificT cells
that do not express either V08.2 or Vf313 TCRs.
Anti-V,8 Antibody TreatmentCan Reverse Paralysis in B10.PL Mice WithEAE.
￿
We next
asked whether the symptoms ofEAE could be reversed with double antibody treat-
ment . Groups of mice were treated with an IgG1 control antibody or with a combi-
nation of antiVf38.2 and antiVO13 3 d after the first signs of MBP-induced paral-
ysis . The animals were then observed on a daily basis and graded for the severity
of paralysis (Fig . 5) . Disease symptoms remained the same or worsened in all five
ofthecontrol antibody-treated animals during the first 2 wk of observation . In con-
trast, dramatic improvements were observed in antiVo treatedanimals within 2-7 d
after antibody injection. Reversal from severe hind legparalysis(grade 3) to acom-
pletely normal phenotype was seen in three of the five antiVO-treated mice. In an-
other antiVf3-treated mouse, a reversal from a near complete whole body paralysis
(grade 4) to a limited tail paralysis (grade 1) was observed . One anti-Vf3-treated
mousethat began with whole body paralysis died 3 d aftertreatment . We conclude
that treatment with thecombination ofantiVfl8.2 and antiVO13 is an effectivetherapy
for the reversal of paralysis in B10YL mice.
Discussion
MBP-induced encephalomyelitis is considered to be a paradigm forT cell-medi-
ated autoimmune disease. Striking similarities in the pathology of EAE and MS
in humans make EAE an especially important model system for study. The domi-
nant T cell response to MBP in H-2u mice is directed towards a single NH2-5
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￿
Treatment with antiV,8mAbs results in reversal ofMBP-induced paralysis . Groups
of five B10TL mice matched for severity ofEAE symptoms were treated with either an IgG1
control antibody or acombination ofantiVS8.2 and anti-Vfl13 antibodies. Mice were then scored
daily for disease severity. Each symbol represents the disease score foran individual mouseon
a given day. The lines correspond to the average disease severity of surviving mice in each group
on that day . The solid line represents the control antibody-treated group ; the broken line repre-
sents the antiVs treated group.
terminal determinant and involves T cells that express a limited number of TCR
V-regions . In this report, we demonstratethat in vivoT cell depletion bya combina-
tion of mAbs specific for the TCR Va regions used in the response to MBP is an
effective therapy for both the prevention and treatment of EAE.
Two approaches were used to characterize the T cells involved in the response to
MBP In the first approach, B10.PL mice were immunized withMBP and the re-
sponse was once again recalled in vitro in the presence of blocking antibodies (Fig .
3) . Depletion ofV08.2-expressingT cells before immunization led to a reduction
in MBP responsiveness, while depletion of V013-expressing T cells did not lead to
a significant reduction . This implies that the presence of V#8.2+ T cells is neces-
sary and sufficient for efficient in vivo priming to MBP Simultaneous depletion of
both V08.2- and V013-expressing T cells led to the most dramatic loss in MBP re-
sponsiveness, however, a small proliferative response was still observed. This response
was directed towards the MBP N112-terminal epitope . This suggests that in the ab-
sence ofV08.2- and V013-expressing T cells, subdominantT cells that use alterna-
tive V regionsmight expand in response to MBP immunization . We are now in
the process of further characterizing these T cells .
A single intraperitoneal injection of antiVii antibodies led to a depletion of T
cells expressing corresponding V/3 gene products that lasted -12 wk . T cell elimi-
nation could have resulted from antibody-mediated cytotoxicity, as the mAbs were
a complement fixing isotype, IgGI . However, the emergence ofa small population
of dull staining T cells following antibody treatment (Fig . 2) suggests that down-
modulation of cell surface TCR levels may also play a role . The persistence of T
cell depletion long after the expected clearance of injected V(3-specific antibodies
is puzzling . Presumably, continuedTCRgene rearrangements should lead to arapid
replenishment of the depleted T cell populations. Perhaps, small amounts of the
injected antibodies remained sequestered in locations where they interfered with1952
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T cell development. A previous study demonstrated that the maturation of T cells
expressing particular V regions could be blocked by neonatal injections of a mAb
specific for these V regions (27). Alternatively, injection of V/3-specific antibodies
may stimulate some type of regulatory networkin which thedevelopment of T cells
expressing particular V(3 regions is suppressed.
Several immunological approaches have been used successfully to block EAE, in-
cluding injectionof peptideanalogue to an MBP encephalitogenic determinant (26,
28), passive immunization by injection of antibodies specific forCD4 (7, 8) or class
II MHC gene products (29, 30), andactive immunization by injectionof attenuated
MBP-specific T cells (31) or synthetic peptides corresponding to TCR determinants
(32, 33). Active immunization approaches have advantages since a single vaccina-
tion canlead to immunological memory and perhaps apermanent protection; how-
ever, such treatment would be ineffective for individuals that are nonresponsive to
the vaccinating antigens.
The ability to suppress the response to MBP by injections of V(3-specific anti-
bodies permits analysis of antibody treatment as a strategy to block EAE. This treat-
ment eliminates all V08.2-expressing cells, irrespective of the Va chain they may
be associated with. It is possible that the in vivo elimination of T cell subsets that
express particular V region subfamily members could lead to reduced immune re-
sponsiveness andconsequentialincrease in susceptibility to environmental pathogens.
However, this seems unlikely in light of the fact that inbred mouse strains that lack
50% of the known V(3 genes (SJL, C57L, C57BR, and SWR) do not exhibit ob-
vious immunodeficiencies (34) .
In one series ofexperiments, antibodies were administered before MBP immuni-
zation to test the efficacy of this treatment in preventing EAE (Table II). Injection
of antiVO8.2 (F23 .2) by itself resulted in a significant reduction in EAE incidence
(82.4 to 25%). This finding is consistent with previous reports of partial protection
against EAE after treatment with a V(08-specific antibody (F23 .1) (21) or a V08.2,
V08.3-specific antibody (KJ16) (22). The use of F23.2 for therapy is preferential
to the use of either F23.1 or KJ16, since the later reagents have broader specificities
that wouldlead to the elimination oflarger percentages ofnon-MBP-specific Tcells.
Injection of both antiVO13 and antiVO8.2 resulted in an enhanced reduction in
EAE incidence when compared with injection of Va8.2 alone (25% to 5%). This
result suggests that the failure ofantiVO8.2 to protect animalscompletely from EAE
was due, at least in part, to the continued presence of MBP-reactive V013+ T cells.
One animal in our study with double antibody treatment developed a delayed out-
break of tail paralysis. It is likely that rare Va8.2 -, V013 -, MBP-specific T cells
occasionally expand and can lead an autoimmune attack. This explanation is con-
sistent with the observation that draining lymph node cellsisolated from this mouse
could respond in vitro to MBP and the response could not be blocked by the addition
ofeither antiV08.2 or antiVO13 (Fig. 4). Characterization of apanel ofMBP-specific
hybridoma cells produced from T cells isolated from this mouse is now underway
and should lead to the identification of theTCRs responsible forthese residual MBP
response's. Preliminary analysis indicates that a large majority of these hybridomas
are specific for the MBP NH2-terminal epitope and that none of these hybridomas
express either V08.2 or V013 TCRs.ZALLER ET AL.
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We have also demonstrated that antiV(3 treatment can rapidly reverse the para-
lytic symptoms of EAE (Fig. 5). This observation confirms previous resultsdemon-
strating reversal ofEAE aftertreatment with KJ16 (22). This suggests that themain-
tenance ofan EAE diseasestatemust requirethe constant presence ofMBP-reactive
T cells. Neurological damage associated with EAE may be readily reversed once
autoaggressive T cells are removed. Relapses have not been in any of the double
antibody-treated animals during the first 10 wk of post-treatment observations.
Therapeutic strategies using antibodies reactive to TCR idiotypic determinants
would have the advantage of deleting only very specific subsets of T cells. In fact,
a clonotypic antibody raised against an MBP-specific rat T cell hybridomahas been
shownto protect rats from EAE(35). In practice, it mayprove difficult to raiseanti-
idiotypic antibodies that can crossreact with encephalitogenic T cells from different
individuals. Accordingly, V(3 and/or Va-specific antibodies will constitute a more
useful set of general reagents for autoimmune T cell elimination. In addition, since
the deletions of all T cells with particular V regions (e.g., V08.2 or Vf13) do not
appear to immunologically compromise the animal, the generation of antibodies
to the 22 different murine VO regions may generate a specific set of reagents that
will permit the deletion of any particular subset of T cells. Humans encode some-
where between 50 and 75 functional V/3 gene segments.
Summary
Experimental allergic encephalomyelitis (EAE)is amodelsystem for Tcell-medi-
ated autoimmune disease. Symptoms of EAE are similar to those of multiple scle-
rosis (MS) in humans. EAE is induced in susceptible animal strains by immuniza-
tion with myelin basicprotein(MBP) and potent adjuvant. ThemajorTcell response
to MBP in B10.PL mice is directed towards an NH2-terminal epitope and involves
Tcells expressing either Va8.2 or Vfl3 gene segments. Animals treated with aTCR
V/38-specificmAbhave areduced incidence of EAE. We report here that thein vivo
administration ofa combinationof antiVa8.2 and antiV/311 mAbs'results in along-
term elimination of T cells involved in the response to MBP When given before
MBP immunization, antiTCR antibody treatmentleads to nearly complete protec-
tion against EAE. Antibody treatment also resultsin adramatic reversal of paralysis
in diseased animals. Thus, treatment with a combination of Vf-specific antibodies
is a very effective therapy for the prevention and treatment of EAE. It is hoped that
the future characterization of TCR V gene usage in human autoimmune diseases
may lead to similar strategies of immune intervention.
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